NOVIGENIX
Novigenix is a pioneering Swiss TechBio company specializing in Immuno-Transcriptomics, delivering AI-driven liquid biopsy multi-omic solutions via its proprietary LITOSeek™ AI-RNA analytics platform. The company focuses on early cancer detection, precision medicine, and innovative drug target discovery, primarily in oncology. Novigenix's platform analyzes patient blood RNA and immune response signatures to provide precise and predictive data on cancer risk, stage, and likely response to immunotherapy, enabling better patient outcomes and accelerating drug development. It has a proven track record with a best-in-class blood test for early colorectal cancer detection in the Swiss market and collaborates closely with biopharma companies and academic centers. Novigenix holds ISO 13485 certification and has received significant EU research funding, positioning it as a leader in AI-powered precision oncology solutions.
NOVIGENIX
Novigenix is a pioneering Swiss TechBio company specializing in Immuno-Transcriptomics, delivering AI-driven liquid biopsy multi-omic solutions via its proprietary LITOSeek™ AI-RNA analytics platform. The company focuses on early cancer detection, precision medicine, and innovative drug target discovery, primarily in oncology. Novigenix's platform analyzes patient blood RNA and immune response signatures to provide precise and predictive data on cancer risk, stage, and likely response to immunotherapy, enabling better patient outcomes and accelerating drug development. It has a proven track record with a best-in-class blood test for early colorectal cancer detection in the Swiss market and collaborates closely with biopharma companies and academic centers. Novigenix holds ISO 13485 certification and has received significant EU research funding, positioning it as a leader in AI-powered precision oncology solutions.